

Form 51-102F3
Material Change Report

1. Name and Address of Company

Enttheon Biomedical Corp.
Suite 720 - 999 W Broadway Street
Vancouver, BC
V5Z 1K5
(the "Company")

2. Dates of Material Change(s)

November 30, 2022

3. News Release(s)

News release was issued on November 30, 2022 and disseminated via Stockwatch pursuant to section 7.1 of National Instrument 51-102.

4. Summaries of Material Changes

The Company announces it will be ceasing sales of HaluGen and Lobo Direct-To-Consumer ("DTC") genetic testing kits.

5. Full Description of Material Changes

News Release dated November 30, 2022– See Schedule "A".

6. Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

7. Omitted Information

No information has been omitted.

8. Executive Officer

Mr. Timothy Ko, President, CEO and Director of the Company, is knowledgeable about the material change contained herein and may be reached at (604) 562-3932.

9. Date of Report

This report is dated December 6, 2022

Entheon Provides Corporate Update on HaluGen Life Sciences and Lobo Genetics

Vancouver, British Columbia--(November 30, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is providing an update on its two wholly-owned subsidiaries, HaluGen Life Sciences Inc. ("HaluGen") and Lobo Genetics Inc. ("Lobo").

As part of Entheon's continued efforts to re-focus resources, Entheon will be ceasing sales of HaluGen and Lobo Direct-To-Consumer ("DTC") genetic testing kits. Existing customers can continue to access their genetic test results at www.HaluGen.com and www.LoboGene.com.

Any additional customer inquiries can be sent to: support@halugen.com and support@lobogene.com.

About HaluGen Life Sciences Inc.

HaluGen has developed a DNA testing and personalized psychedelic pre-screening platform that provides genetic, personal and familial insights to better inform the psychedelic experience, with the goal of improving patient care and reducing side effects and risk. HaluGen's genetic-based psychedelic pre-screening platform helps evaluate an individual's overall sensitivity and risk profile when using hallucinogenic drugs. This platform is the first of its kind with test results within days.

About Lobo Genetics Inc.

Lobo is a personalized genetics company with a direct-to-consumer (DTC) platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoactive drugs.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

<https://entheonbiomedical.com/>